Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10667354 | 0.82 | L3MBTL1 (0.37) | NQO1L3MBTL1TUBB1CYP1A2CYP2D6 | |
| SCHEMBL28025673 | 0.80 | NR5A1 (0.39) | TLR4 | |
| SCHEMBL1491066 | 0.77 | KDM4E (0.32) | — | |
| SCHEMBL16395449 | 0.76 | SYK (0.35) | SYK | |
| SCHEMBL15066775 | 0.76 | TLR4 (0.36) | TLR4HTR2AHTR2CHTR2B | |
| SCHEMBL16395022 | 0.76 | POLB (0.36) | — | |
| SCHEMBL2167840 | 0.72 | TLR4 (0.31) | NQO1L3MBTL1TUBB1TLR4HTR2A | |
| SCHEMBL1003999 | 0.72 | L3MBTL1 (0.38) | NQO1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL455887 | 0.72 | NQO1 (0.34) | NQO1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1547887 | 0.72 | L3MBTL1 (0.48) | NQO1L3MBTL1TUBB1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862691-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2018-01-09 | — | — | US | claimed |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2016-10-27 | — | — | US | claimed |
| US-8748599-B2 | Cyclic triazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2014-06-10 | — | — | US | claimed |
| US-20120135992-A1 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2012-05-31 | — | — | US | claimed |
| EP-2451806-A2 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2012-05-16 | — | — | EP | claimed |
| WO-2011004195-A2 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2011-01-13 | — | — | WO | claimed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9862691-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2018-01-09 | — | — | US | disclosed |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2016-10-27 | — | — | US | disclosed |
| US-9422253-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2016-08-23 | — | — | US | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-3002280-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2016-04-06 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20120135992-A1 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2012-05-31 | — | — | US | disclosed |
| EP-2451806-A2 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2012-05-16 | — | — | EP | disclosed |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2011-01-13 | — | — | US | disclosed |
| WO-2011004195-A2 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2011-01-13 | — | — | WO | disclosed |
| EP-2229371-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009090431-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135992-A1 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | SCN5A, SCN1B, KCNH2 | NQO1 1627/4885L3MBTL1 2496/4885TUBB1 574/4885 |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | CACNA1E, SCN2B, SCN3A | NQO1 801/4885L3MBTL1 1300/4885TUBB1 241/4885 |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | NQO1 3/4885L3MBTL1 2609/4885TUBB1 2026/4885 |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | SCN1A, SCN1B, SCN3A | NQO1 975/4885L3MBTL1 4016/4885TUBB1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.